• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Sebaceous gland carcinoma: analysis based on the 8 edition of American Joint Cancer Committee classification.皮脂腺癌:基于美国癌症联合委员会第 8 版分类的分析。
Eye (Lond). 2023 Mar;37(4):714-719. doi: 10.1038/s41433-022-02025-2. Epub 2022 Mar 26.
2
Prognosis of eyelid sebaceous gland carcinoma based on the tumor (T) category of the American Joint Committee on Cancer (AJCC) classification.基于美国癌症联合委员会(AJCC)分类的肿瘤(T)类别对眼睑皮脂腺癌的预后评估
Int Ophthalmol. 2016 Oct;36(5):681-90. doi: 10.1007/s10792-016-0187-6. Epub 2016 Feb 1.
3
Eyelid sebaceous carcinoma: Validation of the 8th edition of the American Joint Committee on cancer T staging system and the prognostic factors for local recurrence, nodal metastasis, and survival.眼睑皮脂腺癌:第 8 版美国癌症联合委员会 T 分期系统的验证及局部复发、淋巴结转移和生存的预后因素。
Eye (Lond). 2019 Jun;33(6):887-895. doi: 10.1038/s41433-019-0454-7. Epub 2019 May 31.
4
Iris Melanoma Outcomes Based on the American Joint Committee on Cancer Classification (Eighth Edition) in 432 Patients.432 例患者中基于美国癌症联合委员会分类(第八版)的虹膜黑色素瘤结局。
Ophthalmology. 2018 Jun;125(6):913-923. doi: 10.1016/j.ophtha.2017.11.040. Epub 2018 Jan 17.
5
Eyelid sebaceous gland carcinoma, validation of AJCC 8th edition T staging- a retrospective study from North India.眼睑皮脂腺癌 AJCC 第 8 版 T 分期的验证-来自印度北部的回顾性研究。
Acta Ophthalmol. 2023 Feb;101(1):49-56. doi: 10.1111/aos.15204. Epub 2022 Jun 24.
6
Association of T and N Categories of the American Joint Commission on Cancer, 8th Edition, With Metastasis and Survival in Patients With Orbital Sarcoma.美国癌症联合委员会第 8 版 T 和 N 分类与眼眶肉瘤患者转移和生存的关系。
JAMA Ophthalmol. 2020 Apr 1;138(4):374-381. doi: 10.1001/jamaophthalmol.2020.0039.
7
American Joint Committee on Cancer (AJCC) clinical classification predicts conjunctival melanoma outcomes.美国癌症联合委员会(AJCC)临床分类预测结膜黑色素瘤的结局。
Ophthalmic Plast Reconstr Surg. 2012 Sep-Oct;28(5):313-23. doi: 10.1097/IOP.0b013e3182611670.
8
Eyelid sebaceous gland carcinoma: An assessment of the T classification of the American Joint Committee of Cancer TNM staging system 8th versus 7th edition.眼睑皮脂腺癌:第 8 版美国癌症联合委员会 TNM 分期系统与第 7 版 T 分类的评估。
Eur J Ophthalmol. 2021 Jul;31(4):2055-2063. doi: 10.1177/1120672120936488. Epub 2020 Jun 21.
9
Prognostic factors for local recurrence, metastasis and survival for sebaceous carcinoma of the eyelid: observations in 100 patients.眼睑皮脂腺癌局部复发、转移和生存的预后因素:100 例患者观察。
Br J Ophthalmol. 2019 Jul;103(7):980-984. doi: 10.1136/bjophthalmol-2018-312635. Epub 2018 Aug 21.
10
American Joint Committee on Cancer T category for eyelid sebaceous carcinoma correlates with nodal metastasis and survival.美国癌症联合委员会(AJCC)眼睑皮脂腺癌 T 分期与淋巴结转移和生存相关。
Ophthalmology. 2012 May;119(5):1078-82. doi: 10.1016/j.ophtha.2011.11.006. Epub 2012 Feb 11.

引用本文的文献

1
Multimodal treatment with Neoadjuvant chemotherapy for eyelid and periocular sebaceous gland carcinoma: Long-term outcomes.眼睑及眼周皮脂腺癌新辅助化疗的多模式治疗:长期疗效
Am J Ophthalmol Case Rep. 2025 Feb 5;38:102272. doi: 10.1016/j.ajoc.2025.102272. eCollection 2025 Jun.
2
Molecular landscape of eyelid sebaceous gland carcinoma: A comprehensive review.眼睑皮脂腺癌的分子特征:全面综述。
Indian J Ophthalmol. 2024 Oct 1;72(10):1393-1403. doi: 10.4103/IJO.IJO_167_24. Epub 2024 Sep 27.

本文引用的文献

1
Differences in 7th and 8th edition American Joint Committee on Cancer staging for periocular sebaceous carcinoma.美国癌症联合委员会第7版和第8版眼周皮脂腺癌分期的差异。
Can J Ophthalmol. 2021 Feb;56(1):31-36. doi: 10.1016/j.jcjo.2020.07.017. Epub 2020 Aug 18.
2
Eyelid sebaceous gland carcinoma: An assessment of the T classification of the American Joint Committee of Cancer TNM staging system 8th versus 7th edition.眼睑皮脂腺癌:第 8 版美国癌症联合委员会 TNM 分期系统与第 7 版 T 分类的评估。
Eur J Ophthalmol. 2021 Jul;31(4):2055-2063. doi: 10.1177/1120672120936488. Epub 2020 Jun 21.
3
Eyelid sebaceous carcinoma: Validation of the 8th edition of the American Joint Committee on cancer T staging system and the prognostic factors for local recurrence, nodal metastasis, and survival.眼睑皮脂腺癌:第 8 版美国癌症联合委员会 T 分期系统的验证及局部复发、淋巴结转移和生存的预后因素。
Eye (Lond). 2019 Jun;33(6):887-895. doi: 10.1038/s41433-019-0454-7. Epub 2019 May 31.
4
Prognostic factors for local recurrence, metastasis and survival for sebaceous carcinoma of the eyelid: observations in 100 patients.眼睑皮脂腺癌局部复发、转移和生存的预后因素:100 例患者观察。
Br J Ophthalmol. 2019 Jul;103(7):980-984. doi: 10.1136/bjophthalmol-2018-312635. Epub 2018 Aug 21.
5
Change in Eyelid Carcinoma T Category With Use of the 8th Versus 7th Edition of the American Joint Committee on Cancer: Cancer Staging Manual.第 8 版与第 7 版美国癌症联合委员会癌症分期手册中眼睑癌 T 分类的变化。
Ophthalmic Plast Reconstr Surg. 2019 Jan/Feb;35(1):38-41. doi: 10.1097/IOP.0000000000001133.
6
Prognosis of eyelid sebaceous gland carcinoma based on the tumor (T) category of the American Joint Committee on Cancer (AJCC) classification.基于美国癌症联合委员会(AJCC)分类的肿瘤(T)类别对眼睑皮脂腺癌的预后评估
Int Ophthalmol. 2016 Oct;36(5):681-90. doi: 10.1007/s10792-016-0187-6. Epub 2016 Feb 1.
7
Sebaceous carcinoma in Japanese patients: clinical presentation, staging and outcomes.日本患者的皮脂癌:临床表现、分期和结果。
Br J Ophthalmol. 2013 Nov;97(11):1459-63. doi: 10.1136/bjophthalmol-2013-303758. Epub 2013 Sep 13.
8
Observational prospective cohort study of patients with newly-diagnosed ocular sebaceous carcinoma.初诊眼部皮脂腺癌患者的观察性前瞻性队列研究。
Br J Ophthalmol. 2013 Jan;97(1):47-51. doi: 10.1136/bjophthalmol-2012-302443. Epub 2012 Oct 31.
9
American Joint Committee on Cancer T category for eyelid sebaceous carcinoma correlates with nodal metastasis and survival.美国癌症联合委员会(AJCC)眼睑皮脂腺癌 T 分期与淋巴结转移和生存相关。
Ophthalmology. 2012 May;119(5):1078-82. doi: 10.1016/j.ophtha.2011.11.006. Epub 2012 Feb 11.
10
Feasibility of using American Joint Committee on Cancer Classification criteria for staging eyelid carcinomas.采用美国癌症联合委员会(AJCC)分期标准对眼睑癌进行分期的可行性。
Orbit. 2011 Oct;30(5):202-7. doi: 10.3109/01676831003664343.

皮脂腺癌:基于美国癌症联合委员会第 8 版分类的分析。

Sebaceous gland carcinoma: analysis based on the 8 edition of American Joint Cancer Committee classification.

机构信息

Operation Eyesight Universal Institute for Eye Cancer, L V Prasad Eye Institute, Hyderabad, India.

Ophthalmic Biophysics (AMd), L V Prasad Eye Institute, Hyderabad, India.

出版信息

Eye (Lond). 2023 Mar;37(4):714-719. doi: 10.1038/s41433-022-02025-2. Epub 2022 Mar 26.

DOI:10.1038/s41433-022-02025-2
PMID:35347292
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9998849/
Abstract

PURPOSE

To assess the prognostic value of T category of the 8 edition of American Joint Committee on Cancer (AJCC) classification in periocular sebaceous gland carcinoma (SGC).

METHODS

Retrospective interventional case series of 119 cases.

RESULTS

Based on the T category of 8th edition of AJCC classification, 119 periocular SGCs were classified into T1 (n = 33, 28%), T2 (n = 37, 31%) T3 (n = 17, 14%) and T4 (n = 32, 27%). There were no statistically significant differences in the rate of tumour recurrence based on T category. The outcome measures that showed significant increase with increase in T category included regional lymph node metastasis (3% for T1, 3% for T2, 12% for T3, and 44% for T4; p < 0.0001), systemic metastasis (0% for T1, 0% for T2, 12% for T3, and 25% for T4; p = 0.002) and death due to metastasis (0% for T1, 0% for T2, 12% for T3, and 22% for T4; p = 0.005). The 5-year Kaplan-Meier estimate rate for regional lymph node metastasis, systemic metastasis and metastasis-related death were all higher for the T4 category tumours (42%, p = 0.005; 34%, p = 0.0002; and 43%, p = 0.0001 respectively) compared to T1 (9%, 0%, and 0%), T2 (5%, 0%, and 0%) and T3 (10%, 17 and 8%) tumours.

CONCLUSION

Primary tumour (T) category of the 8 edition AJCC classification predicts the prognosis of patients with periocular SGC. The rates of lymph node metastasis, systemic metastasis, and death is much higher in T4 tumours compared to T1, T2, and T3 tumours. There was no association between T category and tumour recurrence.

摘要

目的

评估第 8 版美国癌症联合委员会(AJCC)分类中 T 分期在眼周皮肤腺癌(SGC)中的预后价值。

方法

回顾性干预性病例系列研究,共纳入 119 例患者。

结果

根据第 8 版 AJCC 分类的 T 分期,119 例眼周 SGC 分为 T1(n=33,28%)、T2(n=37,31%)、T3(n=17,14%)和 T4(n=32,27%)。根据 T 分期,肿瘤复发率无统计学差异。随着 T 分期的增加,以下指标的结果显著增加:区域淋巴结转移(T1 为 3%,T2 为 3%,T3 为 12%,T4 为 44%;p<0.0001)、全身转移(T1 为 0%,T2 为 0%,T3 为 12%,T4 为 25%;p=0.002)和因转移导致的死亡(T1 为 0%,T2 为 0%,T3 为 12%,T4 为 22%;p=0.005)。T4 类肿瘤的 5 年 Kaplan-Meier 估计区域淋巴结转移、全身转移和转移相关死亡率均高于 T1 类肿瘤(42%,p=0.005;34%,p=0.0002;和 43%,p=0.0001)、T2 类肿瘤(5%,0%和 0%)和 T3 类肿瘤(10%,17%和 8%)。

结论

第 8 版 AJCC 分类中的原发肿瘤(T)分期预测了眼周 SGC 患者的预后。与 T1、T2 和 T3 肿瘤相比,T4 肿瘤的淋巴结转移、全身转移和死亡的发生率要高得多。T 分期与肿瘤复发之间没有关联。